Nexalin Technology (NASDAQ:NXL) versus IMRIS (OTCMKTS:IMRSQ) Head to Head Analysis

IMRIS (OTCMKTS:IMRSQ) and Nexalin Technology (NASDAQ:NXL) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a summary of current ratings and target prices for IMRIS and Nexalin Technology, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IMRIS	0	0	0	0	0.00
Nexalin Technology	0	1	0	0	2.00

Nexalin Technology has a consensus price target of $3.00, suggesting a potential upside of 10.29%. Given Nexalin Technology’s stronger consensus rating and higher possible upside, analysts clearly believe Nexalin Technology is more favorable than IMRIS.

Earnings and Valuation

This table compares IMRIS and Nexalin Technology”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IMRIS	N/A	N/A	N/A	N/A	N/A
Nexalin Technology	$162,078.00	223.27	-$4.65 million	($0.64)	-4.25

IMRIS has higher earnings, but lower revenue than Nexalin Technology.

Profitability

This table compares IMRIS and Nexalin Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IMRIS	N/A	N/A	N/A
Nexalin Technology	-3,407.98%	-187.59%	-167.21%

Insider & Institutional Ownership

0.6% of Nexalin Technology shares are owned by institutional investors. 24.0% of Nexalin Technology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Nexalin Technology beats IMRIS on 5 of the 8 factors compared between the two stocks.

About IMRIS

IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions worldwide. The company offers VISIUS Surgical Theatres, a surgical environment that provides intraoperative vision to clinicians to assist in decision-making and enhance precision in treatment. Its VISIUS Surgical Theatre incorporates magnetic resonance imaging, computed tomography, and fluoroscopy into multi-purpose surgical suites to provide intraoperative imaging for specific medical applications by bringing advanced imaging into the operating room (OR). The company sells the VISIUS Surgical Theatres to hospitals that deliver clinical services to patients in the neurosurgical, spinal, cerebrovascular, and cardiovascular markets. It also provides service and extended maintenance contracts, and accessories and disposables. The company was founded in 2005 and is based in Winnipeg, Canada.

About Nexalin Technology

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.